Agennix AG Schedules Conference Call on November 30, 2012 to Discuss Third Quarter 2012 Financial Results

  Corporate news transmitted by euro adhoc. The issuer/originator is solely
  responsible for the content of this announcement.
Company Information

Planegg/Munich (Germany) and Princeton, NJ, November 6, 2012 (euro adhoc) -
Agennix AG (Frankfurt Stock Exchange: AGX) today announced that the Company will
hold a conference call to discuss financial results for the third quarter and
first nine months of 2012 and to provide a business update. The results will be
published on Friday, November 30, 2012 in advance of the conference call. Please
note that this date is a change from the previously announced date of November
8, 2012.

The conference call, which will be conducted in English, will be held on Friday,
November 30, 2012 at 9 AM EST/3 PM CET.  A live webcast will be available on the
Agennix Web site at A replay will be available via the Web site
following the live event. 

Dial-in numbers for the call are as follows:

Participants from Europe:         0049 (0)69 710 445 598        
                                  0044 (0)20 3003 2666 
Participants from the U.S.:       1 212 999 6659

Please dial in 10 minutes before the beginning of the call.

About Agennix
Agennix AG is a publicly listed biopharmaceutical company that is focused on the
development of novel therapies that have the potential to substantially lengthen
and improve the lives of critically ill patients in areas of major unmet medical
need. The Company's clinical development programs include oral talactoferrin
alfa; RGB-286638, a multi-targeted kinase inhibitor; and a topical gel form of
talactoferrin.  Agennix's registered seat is in Heidelberg, Germany. The Company
has two sites of operation: Planegg/Munich, Germany and Princeton, New Jersey.
For additional information, please visit the Agennix Web site at

This press release contains forward-looking statements, which express the
current beliefs and expectations of the management of Agennix AG, including
statements about cash reach. Such statements are based on current expectations
and are subject to risks and uncertainties, many of which are beyond our
control, that could cause future results, performance or achievements to differ
significantly from those expressed or implied by such forward-looking
statements. Actual results could differ materially depending on a number of
factors, and we caution investors not to place undue reliance on the
forward-looking statements contained in this press release. The achievement of
positive results in early stage clinical studies does not ensure that later
stage clinical studies will be successful.  There can be no guarantee that the
Company will have or be able to obtain the financial resources to conduct
additional studies with its product candidates or that it will be successful in
pursuing other business opportunities. Forward-looking statements speak only as
of the date on which they are made and Agennix undertakes no obligation to
update these forward-looking statements, even if new information becomes
available in the future.

Agennix® is a trademark of Agennix AG.

Further inquiry note:
Barbara Mueller
Manager, Investor Relations & 
Corporate Communications 		
Phone: +49 (0)89 8565 2693		
In the U.S.: Laurie Doyle		
Senior Director, Investor Relations & 
Corporate Communications		
Phone: +1 609 524 5884

end of announcement                               euro adhoc 

company:     AGENNIX AG
             Im Neuenheimer Feld 515
             D-69120 Heidelberg
phone:       +49 89 8565 2693
FAX:         +49 89 8565 2610
sector:      Pharmaceuticals
ISIN:        DE000A1A6XX4
indexes:     CDAX, Prime All Share, Technology All Share
stockmarkets: free trade: Hannover, Berlin, München, Hamburg, Düsseldorf,
             regulated dealing/prime standard: Frankfurt 
language:   English

Weitere Meldungen: AGENNIX AG

Das könnte Sie auch interessieren: